Table 2.

Most common questions with comments.

Q8. Have there been any delays in getting routine bone imaging such as CT due to COVID19? What is the average length of the delay? •≤2 weeks: 3 out of 25 responses − 12% •2–4 weeks: 11 out of 25 responses − 44% •4–8 weeks: 7 out of 25 responses − 28% •More than 8 weeks: 1 out of 25 responses − 4% •Not specified: 3 out of 25 responses − 12%

Q11. Have there been any delays in getting bone scans due to COVID19? what is the average length of the delay? •≤2 weeks: 2 out of 19 responses – 10.5% •2–4 weeks: 8 out of 19 responses – 42.1% •4–8 weeks: 5 out of 19 responses – 26.3% •More than 8 weeks: 2 out of 19 responses − 10.5% •Not specified: 2 out of 19 responses − 10.5%

Q12. Have there been any delays in getting MRI scans due to COVID19? what is the average length of the delay? •≤2 weeks: 2 out of 22 responses – 9% •2–4 weeks: 8 out of 22 responses – 36.3% •4–8 weeks: 6 out of 22 responses – 27.3% •More than 8 weeks: 1 out of 22 responses – 4.5% •Not specified: 5 out of 22 responses – 22.7%

Q13. Has there been an impact on palliative external beam radiotherapy at your centre due to COVID19? What is an average length of the delay? •≤2 weeks: 5 out of 11 responses – 45.4% •2–4 weeks: 2 out of 11 responses – 18.2% •4–8 weeks: 0 out of 11 responses – 0% •More than 8 weeks: 1 out of 11 responses – 9% •Not specified: 3 out of 11 responses – 27.3%

Q14. Has there been an impact upon access to stereotactic radiotherapy at your centre due to COVID19? What is an average length of the delay? •≤2 weeks: 1 out of 8 responses – 12.5% •2–4 weeks: 2 out of 8 responses – 25% •4–8 weeks: 1 out of 8 responses – 12.5% •More than 8 weeks: 2 out of 8 responses – 25% •Not specified: 2 out of 8 responses – 25%

Q16. What percentage of your patients with bone metastases have been having remote follow-up? •0–10%: 6 out of 29 responses: 20.7% •11–30%: 2 out of 29 responses: 6.9% •31–50%: 4 out of 29 responses: 13.8% •51–80%: 6 out of 29 responses: 20.7% •81–100%: 9 out of 29 responses: 31% •Not specified: 2 out of 29 responses: 6.9%

Q41. Have bone directed clinical trials been affected at your institution during COVID19? •Many temporarily interrupted. •Recruitment halted. •Difficult to start or plan new trials •Some trials concluding with reduced recruitment •Issues with patient sampling •Issues with data capture

Q42. Have bone oriented or cancer-oriented labs been affected at your institution during COVID19? •Most labs were closed during lockdown (March to June). •Ongoing restrictions and reduced capacity after reopening •Animal experiments especially affected •Longer timescale experiments almost impossible •Substantial staffing issues •Funding issues in terms of grant extensions

Q43. Have the trainees in the cancer and bone field experienced significant changes to their learning opportunities during COVID19? •Mostly remote learning and interaction, no face-to-face meetings. •Inability to perform experiments in the labs and delays in completion of doctoral projects. •Less clinic exposure and face-to-face consultations. More telephone/virtual clinics. •Trainee redeployment to covid areas.

Q44. Have there been financial constraints to cancer and bone research funding during COVID19? •Research funding reduced. •Few grants opening, less non-COVID funding available. What steps are you or your institution taking to compensate for any lapse in training or research projects? •Possibility to extend doctoral contracts •Prioritising writing of manuscripts and data analysis.